Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
- PMID: 29092786
- DOI: 10.1016/j.jaip.2017.09.016
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
Abstract
Background: Peanut oral immunotherapy, using a variety of approaches, has been previously shown to induce desensitization in peanut-allergic subjects, but no products have been approved for clinical use by regulatory agencies.
Objective: We performed the first phase 2 multicentered study to assess the safety and efficacy of AR101, a novel oral biologic drug product.
Methods: A randomized, double-blind, placebo-controlled trial was conducted at 8 US centers. Eligible subjects were 4 to 26 years old, sensitized to peanut, and had dose-limiting symptoms to ≤143 mg of peanut protein in a screening double-blind, placebo-controlled food challenge (DBPCFC). Subjects were randomized 1:1 to daily AR101 or placebo and gradually up-dosed from 0.5 to 300 mg/day. The primary endpoint was the proportion of subjects in each arm able to tolerate ≥443 mg (cumulative peanut protein) at exit DBPCFC with no or mild symptoms.
Results: Fifty-five subjects (29 AR101, 26 placebo) were enrolled. In the intention-to-treat analysis, 23 of 29 (79%) and 18 of 29 (62%) AR101 subjects tolerated ≥443 mg and 1043 mg at exit DBPCFC, respectively, versus 5 of 26 (19%) and 0 of 26 (0%) placebo subjects (both P < .0001). Compared with placebo, AR101 significantly reduced symptom severity during exit DBPCFCs and modulated peanut-specific cellular and humoral immune responses. Gastrointestinal (GI) symptoms were the most common treatment-related adverse events (AEs) in both groups, with 6 AR101 subjects (21%) withdrawing, 4 of those due primarily to recurrent GI AEs.
Conclusions: In this study, AR101 demonstrated an acceptable safety profile and demonstrated clinical activity as a potential immunomodulatory treatment option in peanut-allergic children over the age of 4, adolescents, and young adults.
Keywords: AR101; ARC001; Desensitization; Double-blind placebo-controlled trial; Food allergy; OIT; Oral immunotherapy; Peanut allergy.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.Lancet Child Adolesc Health. 2020 Oct;4(10):728-739. doi: 10.1016/S2352-4642(20)30234-0. Epub 2020 Jul 20. Lancet Child Adolesc Health. 2020. PMID: 32702315 Clinical Trial.
-
AR101 Oral Immunotherapy for Peanut Allergy.N Engl J Med. 2018 Nov 22;379(21):1991-2001. doi: 10.1056/NEJMoa1812856. Epub 2018 Nov 18. N Engl J Med. 2018. PMID: 30449234 Clinical Trial.
-
Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.Lancet. 2019 Oct 19;394(10207):1437-1449. doi: 10.1016/S0140-6736(19)31793-3. Epub 2019 Sep 12. Lancet. 2019. PMID: 31522849 Free PMC article. Clinical Trial.
-
Allergen-specific oral immunotherapy for peanut allergy.Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD009014. doi: 10.1002/14651858.CD009014.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972130 Free PMC article. Review.
-
Peanut (Arachis hypogaea) allergen powder-dnfp for the mitigation of allergic reactions to peanuts in children and adolescents.Expert Rev Clin Immunol. 2023 Mar;19(3):253-265. doi: 10.1080/1744666X.2023.2159812. Epub 2022 Dec 22. Expert Rev Clin Immunol. 2023. PMID: 36524617 Review.
Cited by
-
Food Allergen Immunotherapy in the Treatment of Patients with IgE-Mediated Food Allergy.Medicina (Kaunas). 2024 Jan 9;60(1):121. doi: 10.3390/medicina60010121. Medicina (Kaunas). 2024. PMID: 38256382 Free PMC article. Review.
-
The Role of Biologics in the Treatment of Food Allergy.J Allergy Clin Immunol Pract. 2024 Mar;12(3):562-568. doi: 10.1016/j.jaip.2023.11.032. Epub 2023 Nov 25. J Allergy Clin Immunol Pract. 2024. PMID: 38013157
-
Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management.Curr Allergy Asthma Rep. 2024 Jun;24(6):303-315. doi: 10.1007/s11882-024-01146-w. Epub 2024 Apr 19. Curr Allergy Asthma Rep. 2024. PMID: 38639896 Review.
-
Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies.Cell Immunol. 2022 Dec;382:104641. doi: 10.1016/j.cellimm.2022.104641. Epub 2022 Nov 14. Cell Immunol. 2022. PMID: 36402002 Free PMC article. Review.
-
Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.J Allergy Clin Immunol. 2020 Mar;145(3):885-896.e6. doi: 10.1016/j.jaci.2019.10.038. Epub 2019 Dec 2. J Allergy Clin Immunol. 2020. PMID: 31805311 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources